What role does 3D genomics have in drug discovery?

In this episode I am joined by Hazel Jones, CEO of Enhanc3d Genomics, to find out more about this cutting-edge technology.

Hazel is a dynamic and flexible senior leader with experience of oncology research, both in pharma/biotech and an academic/charity setting. Making her insights into the workings of not for profit and big pharma invaluable.

We discuss her work at Enhanc3d Genomics and the role of 3D genomics in uncovering the regulatory elements of the genome. As well as its potential in identifying new drug targets and biomarkers. Hazel also shares insights into the challenges and opportunities in the biotech industry and the importance of networking and collaboration to help projects succeed.

Hazel has a wealth of knowledge not just in her specialism but how the whole industry works, so sit tight and get ready to learn!

“We've made huge discoveries both in drugs and diagnosis through genomics.” – Hazel Jones

You’ll hear about:

01:13 - What do Enhanc3d Genomics do?

05:16 - Hazel's experience in not for profit

10:11 - Behind the scenes in big pharma

15:53 - How promoters and enhancers work

24:36 - Regulators and the potential for side effects

31:59 - Hazel on raising money

36:40 - Prevention rather than the cure

37:51 - Hazel on Conexen

Connect with Hazel:

LinkedIn - https://www.linkedin.com/in/joneshazel/
Enhanc3d Genomics - https://enhanc3d-genomics.com/

Connect with me:

LinkedIn: https://www.linkedin.com/in/markdavison100/
Grant Instruments: https://www.grantinstruments.com/
Grant Instruments on LinkedIn: https://www.linkedin.com/company/grant-instruments-cambridge-ltd/